Home / Europe / Poland / Life Sciences & Healthcare

Life Sciences & Healthcare

We work with and have established long-term relationships with the top 100 life sciences and healthcare companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our life sciences and healthcare teams in Central and Eastern Europe advise leading global business groups in the sector on transactions, commercial agreements, compliance, investigations and litigation, very often across multiple jurisdictions in the region and beyond. We can help you to navigate the regulatory landscape and to ensure compliance with both local laws and global policies.

Our co-operation with the team was delightful.
Chambers, 2016

With over 480 international specialist lawyers across CMS and the support of the Life Sciences & Healthcare Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your life sciences and healthcare business. Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics.

With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the life sciences and healthcare sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice.

In Poland we are one of the largest players in the market. The close cooperation of almost 150 lawyers in our Warsaw and Poznan offices allows the Life Sciences & Healthcare Practice to offer comprehensive industry-focused advice. Our clients trust us with their toughest business challenges, spanning from clinical trials, pricing and reimbursement, IP, to high profile compliance issues and M&A transactions.

High­lights of our ex­per­i­ence in Lifes­ci­ences in Po­land
A lead­ing glob­al med­ic­al device and phar­ma­ceut­ic­al com­pany on reg­u­lat­ory is­sues con­cern­ing both med­ic­al devices and medi­cin­al products, in such areas as com­pli­ance, re­im­burse­ment, mar­ket­ing, pro­mo­tion...
29/11/2021
Glob­al Life Sci­ences & Health­care Fest­iv­al 2021 - Vir­tu­al
Join us for this year's Glob­al Life Sci­ences & Health­care Fest­iv­al 2021 - Vir­tu­al from 29 Novem­ber to 2 Decem­ber.  Day 1: Ar­ti­fi­cial In­tel­li­gence in Life Sci­ences & Health­care: New busi­ness mod­els in a chan­ging leg­al en­vir­on­ment­Busi­ness mod­els for AI
06/07/2021
CMS Ex­pert Guide to vac­cine com­pens­a­tion re­gimes
 Vac­cine com­pens­a­tion re­gimes are com­plex and con­stantly chan­ging. Launch­ing such a re­gime dur­ing a glob­al pan­dem­ic cre­ates a situ­ation that is dif­fi­cult to nav­ig­ate and fraught with un­cer­tainty. Be­fore dis­tri­bu­tion began of the products cur­rently on
Comparable

Feed

20/09/2022
Skin­teg­rated Cos­me­ceut­ic­als - is Pharma be­com­ing sexy (again?)
Case Study: Skin­tegra, Skin­teg­rity Cos­me­ceut­ic­als are sexy right now.  They’re less reg­u­lated than the phar­ma­ceut­ic­al in­dustry (al­though don’t let that fool you in­to be­liev­ing you can say whatever...
13/09/2022
UPC Rules of Pro­ced­ure go in­to force with judg­ments to be made pub­lic
The entry in­to force of the Rules of Pro­ced­ure is part of the fi­nal pre­par­a­tions for the United Pat­ent Court (UPC), which is cur­rently ex­pec­ted to start work in early 2023. After the bod­ies of the UPC...
08/09/2022
Ad­vert­ising food sup­ple­ments - are we in for a re­volu­tion?
The top­ic of food sup­ple­ments is re­turn­ing yet again – this time the gov­ern­ment is plan­ning changes con­cern­ing the present­a­tion and ad­vert­ising of food sup­ple­ments. On 2 Septem­ber 2022, in­form­a­tion...
08/09/2022
Can­nabis law and le­gis­la­tion in Po­land
Med­ic­al use Pol­ish le­gis­la­tion does not gen­er­ally al­low the grow­ing of can­nabis that con­tains more than 0.3% THC in flower­ing or fruit­ing tops of plants from which the res­in has not been re­moved (Non-Fibrous...
07/09/2022
Phar­ma­ceut­ic­al ad­vert­ising reg­u­la­tion and med­ic­al device ad­vert­ising in...
1. Which laws are ap­plic­able re­gard­ing ad­vert­ising of medi­cines and med­ic­al devices? The main act provid­ing the leg­al frame­work for ad­vert­ising of medi­cin­al products is the Phar­ma­ceut­ic­al Law of 6 Septem­ber...
30/08/2022
Phar­ma­ceut­ic­al trade marks - a real pain in the bum?
An EU IPO Case Study: Proc­to­LYSY­AL v PRO­COTOL­IZ­IN Sum­mary I al­ways like to start at the end.  No nasty sur­prises and you know what to ex­pect.  In this case study, the trade marks ‘proc­to­LYSY­AL’...
03/08/2022
New reg­u­la­tions on ad­vert­ising med­ic­al devices – what can we ex­pect?
On 28 Ju­ly 2022, a draft Reg­u­la­tion of the Min­is­ter of Health on the ad­vert­ising of med­ic­al devices (the “Draft Reg­u­la­tion”) was pub­lished. The Draft is in­ten­ded to be a cla­ri­fic­a­tion of the tech­nic­al...
02/08/2022
Leg­al is­sues in the meta­verse / Part 4 - Ex­pec­ted im­pact of the EU Ar­ti­fi­cial...
Part 4 - Ex­pec­ted im­pact of the EU Ar­ti­fi­cial In­tel­li­gence Reg­u­la­tion, the meta­verse as a work­place In our first art­icle, we ex­amined the nature of the meta­verse, the shared vir­tu­al world. The emer­gence...
27/07/2022
Leg­al is­sues in the meta­verse / Part 3 - Data pro­tec­tion chal­lenges, the...
Part 3 - Data pro­tec­tion chal­lenges, the im­port­ance of cy­ber­se­cur­ity, ad­vert­ising reg­u­la­tion in the meta­verse In our first art­icle, we ex­amined the nature of the meta­verse, the shared vir­tu­al world...
26/07/2022
European Bolar Pro­vi­sions in Po­land
1. How is Bolar im­ple­men­ted? The Bolar pro­vi­sion was in­tro­duced in Po­land be­fore such ex­emp­tion was in­tro­duced in­to EU law. It has been im­ple­men­ted in­to the Act of 30 June 2000 – In­dus­tri­al Prop­erty...
Comparable
19/07/2022
Leg­al is­sues in the meta­verse / Part 2 - Trade­marks and copy­right, NFTs...
Part 2 - Trade­marks and copy­right, NFTs and civil law prin­ciples in the meta­verse In our first art­icle, we ex­amined the nature of the meta­verse, the shared vir­tu­al world. In the meta­verse, trade in vir­tu­al...
15/07/2022
EU­'s Gen­er­al Court con­firms Com­mis­sion's new mer­ger re­fer­ral policy in...
Un­der Art­icle 22 of the EU Mer­ger Reg­u­la­tion (EU­MR), na­tion­al com­pet­i­tion au­thor­it­ies have the pos­sib­il­ity to re­quest re­fer­ral to the Com­mis­sion of any mer­ger, which does not meet the thresholds of the...